PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS

• US 20100136105A1
• Filed: 11/24/2009
• Published: 06/03/2010
• Est. Priority Date: 06/30/1999
• Status: Abandoned Application

• Current Assignee: Lipocine Inc.
• Original Assignee: Lipocine Inc.
• Inventors: CHEN, FENG-JING, FIKSTAD, DAVID T., GILIYAR, CHANDRASHEKAR, ZHANG, HUIPING, PATEL, MAHESH V.
• Application Number:
  US12/625,309
• Publication Number:
  US 20100136105A1
• Time in Patent Office: Days
• US Class Current: 424/455
• CPC Class Codes: A61B 17/0467 Instruments for cutting sutures surgical cutting instruments A61B17/32
• CPC Class Codes: A61B 17/0483 Hand-held instruments for holding sutures A61B17/0469 takes precedence; other holders for needles or sutures A61B17/06061; surgical forceps A61B17/28; surgical pincettes A61B17/30
• CPC Class Codes: A61B 17/0485 Devices or means, e.g. loops, for capturing the suture thread and threading it through an opening of a suturing instrument or needle eyelet
• CPC Class Codes: A61B 2017/0474 Knot pushers
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 31/355 Tocopherols, e.g. vitamin E
• CPC Class Codes: A61K 31/473 ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/566 having an oxo group in position 17, e.g. estrone
• CPC Class Codes: A61K 31/568 substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
• CPC Class Codes: A61K 31/5685 having an oxo group in position 17, e.g. androsterone
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/585 containing lactone rings, e.g. oxandrolone, bufalin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/08 containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 47/22 Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61K 9/4858 Organic compounds
• CPC Class Codes: A61K 9/4866 : Organic macromolecular compounds
• CPC Class Codes: A61P 5/24 : of the sex hormones
• CPC Class Codes: A61P 5/30 : Oestrogens
• CPC Class Codes: B82Y 5/00 : Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a carrier, where the carrier is formed from a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the carrier forms a clear, aqueous dispersion of the triglyceride and surfactants.

Claims

1. A pharmaceutical composition comprising:

a) a carrier comprising;

i) a triglyceride;

ii) at least two surfactants, at least one of the surfactants being a hydrophilic surfactant; and

b) a therapeutically effective amount of a sex hormone;

wherein the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution in an aqueous solution to a composition ratio of about 100;

1 by weight, the composition forms a dispersion having an average particle size of less than 200 nm.

2. The pharmaceutical composition of claim 1, wherein the sex hormone is progesterone, testosterone or an ester thereof.

3. The pharmaceutical composition of claim 1, wherein the carrier enhances the bioabsorption of the sex hormone.

4. The pharmaceutical composition of claim 1, wherein the carrier increases the rate and extent of absorption of the sex hormone.

5. The pharmaceutical composition of claim 1, wherein the carrier provides for a more rapid onset of therapeutic action, better bioperformance characteristics, or a combination thereof of the sex hormone.

6. The pharmaceutical composition of claim 1, wherein the triglyceride is selected from the group consisting of vegetable oils, fish oils, animal fats, hydrogenated vegetable oils, partially hydrogenated vegetable oils, synthetic triglycerides, fractionated triglycerides, and mixtures thereof.

7. The pharmaceutical composition of claim 1, wherein the hydrophilic surfactant comprises at least one non-ionic hydrophilic surfactant having an HLB value greater than or equal to about 10.

8. The pharmaceutical composition of claim 7, wherein the non-ionic surfactant is selected from the group consisting of alkylglucosides;

alkylmaltosides;

alkylthioglucosides;

lauryl macrogolglycerides;

polyoxyethylene alkyl ethers;

polyoxyethylene alkylphenols;

polyethylene glycol fatty acids esters;

polyethylene glycol glycerol fatty acid esters;

polyoxyethylene sorbitan fatty acid esters;

polyoxyethylene-polyoxypropylene block copolymers;

polyglycerol fatty acid esters;

polyoxyethylene glycerides;

polyoxyethylene sterols;

polyoxyethylene vegetable oils;

polyoxyethylene hydrogenated vegetable oils;

reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols;

sugar esters, sugar ethers;

sucroglycerides; and

mixtures thereof.

9. The pharmaceutical composition of claim 7, wherein the non-ionic hydrophilic surfactant is selected from the group consisting of polyoxyethylene alkylethers;

polyethylene glycol fatty acids esters;

polyethylene glycol glycerol fatty acid esters;

polyoxyethylene sorbitan fatty acid esters;

polyoxyethylene-polyoxypropylene block copolymers;

polyglycerol fatty acid esters;

polyoxyethylene glycerides;

polyoxyethylene vegetable oils;

polyoxyethylene hydrogenated vegetable oils;

reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; and

mixtures thereof.

10. The pharmaceutical composition of claim 9, wherein the polyol is selected from the group consisting of glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, a saccharide, and mixtures thereof.

11. The pharmaceutical composition of claim 1, the hydrophilic surfactant is selected from the group consisting of PEG-35 castor oil, PEG-40 hydrogenated castor oil, PEG-60 corn oil, PEG-25 glyceryl trioleate, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polysorbate 20, polysorbate 80, tocopheryl PEG-1000 succinate, PEG-24 cholesterol, a poloxamer, and mixtures thereof.

12. The pharmaceutical composition of claim 1, wherein the carrier comprises at least one hydrophilic surfactant and at least one hydrophobic surfactant.

13. The pharmaceutical composition of claim 12, wherein the hydrophobic surfactant is selected from the group consisting of oleic acid;

lauric acid;

glyceryl monocaprate;

glyceryl monocaprylate;

glyceryl monolaurate;

glyceryl monooleate;

glyceryl dicaprate;

glyceryl dicaprylate;

glyceryl dilaurate;

glyceryl dioleate;

acetylated monoglycerides;

propylene glycol oleate;

propylene glycol laurate;

polyglyceryl-3 oleate;

polyglyceryl-6 dioleate;

PEG-6 corn oil;

PEG-20 corn oil;

PEG-20 almond oil;

sorbitan monooleate;

sorbitan monolaurate;

POE-4 lauryl ether;

POE-3 oleyl ether;

ethyl oleate;

poloxamers;

cholic acid;

ursodeoxycholic acid;

glycocholic acid;

taurocholic acid;

lithocholic acid;

deoxycholic acid;

chenodeoxycholic acid; and

mixtures thereof.

14. The pharmaceutical composition of claim 1, wherein the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution in an aqueous solution to composition ratio of about 10:

1 by weight, the composition forms a clear aqueous dispersion.

15. The pharmaceutical composition of claim 1, which further comprises at least one additive selected from the group consisting of an antioxidant, a bufferant, an antifoaming agent, a detackifier, a preservative, a chelating agent, a viscomodulator, a tonicifier, a flavorant, a colorant, an odorant, an opacifier, a suspending agent, a binder, a filler, a plasticizer, and a lubricant.

16. The pharmaceutical composition of claim 1, wherein the composition has a triglyceride to surfactant ratio of 2:

100 to 75;

100.

17. The pharmaceutical composition of claim 1, wherein the composition has a triglyceride to surfactant ratio of 15:

100 to 75;

100.

18. A dosage form comprising the pharmaceutical composition of claim 1, wherein the dosage form is selected from the group consisting of a pill, capsule, caplet, tablet, granule, bead and powder.

19. A dosage form comprising the pharmaceutical composition of claim 1, wherein the dosage form is selected from the group consisting of a solution, suspension, emulsion, cream, ointment, lotion, suppository, spray, aerosol, paste, gel, drops, douche, ovule, wafer, troche, cachet, syrup and elixir.

20. The pharmaceutical composition of claim 2, wherein the testosterone ester is testosterone enanthate, testosterone proprionate, testosterone undecanoate, testosterone palmitate, or a combination thereof.

21. The pharmaceutical composition of claim 2, wherein the testosterone ester is testosterone enanthate.

22. The pharmaceutical composition of claim 2, wherein the testosterone ester is testosterone proprionate.

23. The pharmaceutical composition of claim 2, wherein the testosterone ester is testosterone undecanoate.

24. The pharmaceutical composition of claim 2, wherein the testosterone ester is testosterone palmitate.

25. A pharmaceutical composition comprising:

a) a triglyceride;

b) a carrier comprising at least two surfactants, at least one of the surfactants being hydrophilic; and

c) a therapeutically effective amount of a sex hormone.

26. The pharmaceutical composition of claim 25, wherein the carrier enhances the bioabsorption of the sex hormone.

27. The pharmaceutical composition of claim 25, wherein the carrier increases the rate and extent of absorption of the sex hormone.

28. The pharmaceutical composition of claim 25, wherein the carrier provides for a more rapid onset of therapeutic action, better bioperformance characteristics, or a combination thereof of the sex hormone.

29. The pharmaceutical composition of claim 25, wherein the triglyceride is selected from the group consisting of vegetable oils, fish oils, animal fats, hydrogenated vegetable oils, partially hydrogenated vegetable oils, synthetic triglycerides, fractionated triglycerides, and mixtures thereof.

30. The pharmaceutical composition of claim 25, wherein the hydrophilic surfactant comprises at least one non-ionic hydrophilic surfactant having an HLB value greater than or equal to about 10.

31. The pharmaceutical composition of claim 30, wherein the non-ionic surfactant is selected from the group consisting of alkylglucosides;

alkylmaltosides;

alkylthioglucosides;

lauryl macrogolglycerides;

polyoxyethylene alkyl ethers;

polyoxyethylene alkylphenols;

polyethylene glycol fatty acids esters;

polyethylene glycol glycerol fatty acid esters;

polyoxyethylene sorbitan fatty acid esters;

polyoxyethylene-polyoxypropylene block copolymers;

polyglycerol fatty acid esters;

polyoxyethylene glycerides;

polyoxyethylene sterols;

polyoxyethylene vegetable oils;

polyoxyethylene hydrogenated vegetable oils;

reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols;

sugar esters, sugar ethers;

sucroglycerides; and

mixtures thereof.

32. The pharmaceutical composition of claim 30, wherein the non-ionic hydrophilic surfactant is selected from the group consisting of polyoxyethylene alkylethers;

polyethylene glycol fatty acids esters;

polyethylene glycol glycerol fatty acid esters;

polyoxyethylene sorbitan fatty acid esters;

polyoxyethylene-polyoxypropylene block copolymers;

polyglycerol fatty acid esters;

polyoxyethylene glycerides;

polyoxyethylene vegetable oils;

polyoxyethylene hydrogenated vegetable oils;

reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; and

mixtures thereof.

33. The pharmaceutical composition of claim 32, wherein the polyol is selected from the group consisting of glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, a saccharide, and mixtures thereof.

34. The pharmaceutical composition of claim 25, the hydrophilic surfactant is selected from the group consisting of PEG-35 castor oil, PEG-40 hydrogenated castor oil, PEG-60 corn oil, PEG-25 glyceryl trioleate, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polysorbate 20, polysorbate 80, tocopheryl PEG-1000 succinate, PEG-24 cholesterol, a poloxamer, and mixtures thereof.

35. The pharmaceutical composition of claim 25, wherein the carrier comprises at least one hydrophilic surfactant and at least one hydrophobic surfactant.

36. The pharmaceutical composition of claim 35, wherein the hydrophobic surfactant is selected from the group consisting of oleic acid;

lauric acid;

glyceryl monocaprate;

glyceryl monocaprylate;

glyceryl monolaurate;

glyceryl monooleate;

glyceryl dicaprate;

glyceryl dicaprylate;

glyceryl dilaurate;

glyceryl dioleate;

acetylated monoglycerides;

propylene glycol oleate;

propylene glycol laurate;

polyglyceryl-3 oleate;

polyglyceryl-6 dioleate;

PEG-6 corn oil;

PEG-20 corn oil;

PEG-20 almond oil;

sorbitan monooleate;

sorbitan monolaurate;

POE-4 lauryl ether;

POE-3 oleyl ether;

ethyl oleate;

poloxamers;

cholic acid;

ursodeoxycholic acid;

glycocholic acid;

taurocholic acid;

lithocholic acid;

deoxycholic acid;

chenodeoxycholic acid; and

mixtures thereof.

37. The pharmaceutical composition of claim 25, which further comprises at least one additive selected from the group consisting of an antioxidant, a bufferant, an antifoaming agent, a detackifier, a preservative, a chelating agent, a viscomodulator, a tonicifier, a flavorant, a colorant, an odorant, an opacifier, a suspending agent, a binder, a filler, a plasticizer, and a lubricant.

38. The pharmaceutical composition of claim 25, wherein the composition has a triglyceride to surfactant ratio of 2:

100 to 75;

100.

39. The pharmaceutical composition of claim 25, wherein the composition has a triglyceride to surfactant ratio of 15:

100 to 75;

100.

40. A dosage form comprising the pharmaceutical composition of claim 25, wherein the dosage form is selected from the group consisting of a pill, capsule, caplet, tablet, granule, bead and powder.

41. A dosage form comprising the pharmaceutical composition of claim 25, wherein the dosage form is selected from the group consisting of a solution, suspension, emulsion, cream, ointment, lotion, suppository, spray, aerosol, paste, gel, drops, douche, ovule, wafer, troche, cachet, syrup and elixir.

42. The pharmaceutical composition of claim 25, wherein the sex hormone is progesterone, testosterone, or an ester thereof.

43. The pharmaceutical composition of claim 25, wherein the sex hormone is testosterone enanthate, testosterone proprionate, testosterone undecanoate, testosterone palmitate, or a combination thereof.

44. The pharmaceutical composition of claim 42, wherein the testosterone ester is testosterone enanthate.

45. The pharmaceutical composition of claim 42, wherein the testosterone ester is testosterone proprionate.

46. The pharmaceutical composition of claim 42, wherein the testosterone ester is testosterone undecanoate.

47. The pharmaceutical composition of claim 42, wherein the testosterone ester is testosterone palmitate.

48. The pharmaceutical composition of claim 25, wherein upon dilution of the composition, the active agent increases the extent of dispersion of the vitamin E substance by at least 20% relative to the dispersion of the composition without the active agent.

49. A pharmaceutical composition comprising:

a) a triglyceride;

b) a hydrophilic alcohol transesterified surfactant; and

c) a therapeutically effective amount of testosterone, or an ester thereof.

50. The pharmaceutical composition of claim 49, wherein the triglyceride is selected from the group consisting of vegetable oils, fish oils, animal fats, hydrogenated vegetable oils, partially hydrogenated vegetable oils, synthetic triglycerides, fractionated triglycerides, and mixtures thereof.

51. The pharmaceutical composition of claim 49, wherein the hydrophilic alcohol transesterified surfactant is selected from the group consisting of PEG-35 castor oil, PEG-40 castor oil, PEG-40 hydrogenated castor oil, or a combination thereof.

52. The pharmaceutical composition of claim 49, wherein the composition has a triglyceride to surfactant ratio of 2:

100 to 75;

100.

53. The pharmaceutical composition of claim 49, wherein the testosterone ester is testosterone undecanoate.

54. A dosage form comprising the pharmaceutical composition of claim 49, wherein the dosage form is selected from the group consisting of a pill, capsule, caplet, tablet, granule, bead and powder.

55. A pharmaceutical composition comprising:

a) a triglyceride;

b) PEG-35 castor oil, PEG-40 castor oil, PEG-40 hydrogenated castor oil, or a combination thereof; and

c) a therapeutically effective amount of testosterone, or an ester thereof.

56. The pharmaceutical composition of claim 55, wherein the triglyceride is selected from the group consisting of vegetable oils, fish oils, animal fats, hydrogenated vegetable oils, partially hydrogenated vegetable oils, synthetic triglycerides, fractionated triglycerides, and mixtures thereof.

57. The pharmaceutical composition of claim 55, wherein the composition has a triglyceride to oil ratio of 2:

100 to 75;

100.

58. The pharmaceutical composition of claim 55, wherein the composition has a triglyceride to surfactant ratio of 15:

100 to 75;

100.

59. The pharmaceutical composition of claim 55, wherein the testosterone ester is testosterone undecanoate.

60. A dosage form comprising the pharmaceutical composition of claim 55, wherein the dosage form is selected from the group consisting of a pill, capsule, caplet, tablet, granule, bead and powder.

61. A method of providing hormone therapy in a patient comprising orally administering to a patient in need thereof a pharmaceutical composition comprising:

a) a therapeutically effective amount of sex hormone;

b) a triglyceride; and

c) a carrier comprising at least two surfactants, at least one of the surfactants being hydrophilic.

62. The method of claim 61, wherein the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution in an aqueous solution to a composition to a composition ratio of about 100:

1 by weight, the composition forms a clear aqueous dispersion having an average particle size of less than 200 nm.